Placeholder Banner

BIO Applauds Declaration on Combating Antimicrobial Resistance

January 21, 2016
Media Contact

Washington, D.C. (January 21, 2016) – The Biotechnology Innovation Organization (BIO) applauds the Industry Declaration on Combating Antimicrobial Resistance, signed by 85 biopharmaceutical and diagnostic companies and released today at the World Economic Forum in Davos, Switzerland.

“Antimicrobial resistance is an urgent public health issue, requiring comprehensive cooperation between all stakeholders, including governments, industry and healthcare providers to properly address,” said BIO President and CEO Jim Greenwood. “Today’s Declaration on Combating Antimicrobial Resistance underscores our industry’s commitment to reducing the development of antimicrobial resistance, investing in R&D of novel products to prevent, diagnose and treat resistant infections, as well as improving access to new and existing antibiotics and vaccines for all patients.

“We echo the Declaration’s call for governments and payers to create a sustainable and predictable market that supports innovation and investment in the development of new products to combat antimicrobial resistance while also maintaining safeguards for their appropriate use. To accomplish these critical goals, the value assigned to antibiotics, diagnostics, vaccines and other novel products addressing antimicrobial resistance should reflect the benefits they bring to society and the investment required for their creation. We welcome the Declaration’s call for value-based reimbursement models, as well as for proposals for new incentive models including those that could reduce the link between financial revenue and usage, such as lump sum payments, insurance-like purchase models, and effective intellectual property-based approaches. We stand ready to work with all stakeholders to ensure that the tremendous public health benefits of antibiotics continue to be available for future generations.” 

Upcoming BIO Events 

BIO International Convention
June 6-9, 2016
San Francisco, Calif.

BIO CEO & Investor Conference
February 8-9, 2016
New York, New York

13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan

BIO-Europe Spring
April 4-6, 2016
Stockholm, Sweden



Discover More
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), yesterday sent a letter to U.S. Trade Representative (USTR) Ambassador Katherine Tai sharing BIO perspectives regarding the proposed WTO “TRIPS waiver”…
Today, Congress passed the “American Rescue Plan” – a $1.9 trillion coronavirus relief package aimed at alleviating some of the economic and health impacts of the COVID-19 pandemic. Upon passage of the bill, Dr. Michelle McMurry-Heath, president…
BIO to assess successes and challenges at its Digital Convention in June